Eisai Inc., a U.S.
subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in
the United States.
As part of this restructuring, Eisai Inc. will reduce its workforce by
approximately 20 percent across all U.S. functions, eliminating
approximately 600 positions in total by April 1, 2011. This organizational
restructuring supports Eisai's global mid-term strategic plan for FY2011-2015,
which seeks to transform Eisai's business into a more efficient and focused organization
to better serve its human health care (hhc) mission. "This restructuring
is essential to our remaining competitive in this rapidly changing
environment," said Lonnel Coats, President and CEO of Eisai Inc. "It
will enable us to continually make the necessary investments in our science,
our people and ultimately our human health care (hhc) mission, while ensuring
an adequate return to our shareholders."
Eisai will focus on accelerating our Oncology portfolio and
launch new neuroscience assets in support of our strong presence in this important
therapeutic area. The new structure is expected to be in place by the start of
FY2011, which begins April 1, 2011. Eisai's U.S. operations include research
and development, manufacturing, sales and marketing, and administrative
functions. The company does not have plans to close any of its main offices or
facilities.
"We are grateful to our colleagues, each of whom has
played an important role in bringing medicines to patients. We are aware of the
impact that our reorganization will have on some employees and will work with
them to ensure that their transition to new careers is as smooth as
possible," said Mr. Coats.